title: Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts.
abstract: The success of treatment of advanced non-small-cell lung cancer (NSCLC) remains very poor. The aim of this study was, on a series of NSCLC xenografts, to compare the efficacy of standard cisplatin-based or docetaxel-based chemotherapy. Seven human xenografts were obtained from six patients (two xenografts were derived from primary or metastatic tumors of the same patient). Three xenografts were adenocarcinomas and four were squamous cell carcinomas. All xenografts reproduced the same histology as that of the patient's original tumor. Docetaxel, administered as single-agent chemotherapy, induced a significant response in five of the seven NSCLC xenografts (71%), without significant increase after combination with cisplatin, vinorelbine, or gemcitabine. Relative expression of genes putatively involved in drug response was also studied in all xenografts and did not explain the variability of drug sensitivity. In conclusion, this panel of human NSCLC xenografts reliably reproduces the data obtained in patient tumors and the relative sensitivity to docetaxel reported in NSCLC patients.
authors.affiliation: Preclinical Investigation Laboratory, Department of Translational Research, Hôpital Européen Georges Pompidou, Paris, France.
authors.forename: Fariba
authors.initials: F
authors.lastname: Némati
authors.forename: Rui
authors.initials: R
authors.lastname: Bras-Gonçalves
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Fontaine
authors.forename: Gonzague
authors.initials: G
authors.lastname: de Pinieux
authors.forename: Patricia
authors.initials: P
authors.lastname: De Cremoux
authors.forename: Alain
authors.initials: A
authors.lastname: Chapelier
authors.forename: Catherine
authors.initials: C
authors.lastname: Daniel
authors.forename: Pierre
authors.initials: P
authors.lastname: Laurent-Puig
authors.forename: Alain
authors.initials: A
authors.lastname: Livartowski
authors.forename: Jean-Gabriel
authors.initials: JG
authors.lastname: Judde
authors.forename: Vincent
authors.initials: V
authors.lastname: Bordier
authors.forename: Marie-France
authors.initials: MF
authors.lastname: Poupon
authors.forename: Didier
authors.initials: D
authors.lastname: Decaudin
mesh_terms: D000368:Aged; D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D016158:Genes, p53 / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D043823:Taxoids / Q000494:pharmacology / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays / Q000379:methods
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin